CD4 and cancer: In addition, among the immunogenic neoantigen epitopes screened from three different mouse models of melanoma, colon cancer and breast cancer, 80–90% of immunogenic neoantigen epitopes screened in mouse models of some cancers were recognized by CD4+T cells rather than CD8+T cells, suggesting that tumor-specific neoantigens may bind more easily to MHC- II than to more restrictive MHC-I [122].